Retrospective Review of Cachexia in Lung and Gastrointestinal Cancer Patients
Study Details
Study Description
Brief Summary
The objective is to perform a retrospective chart review of patients with cachexia related to cancer in patients treated in the palliative care clinic at Parkland Memorial Hospital to evaluate the prognosis and practice patterns in management of cachexia and associated symptoms.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
The definition of cachexia has not been fully elucidated, but there are many similar parameters and guidelines associated with identifying patients with cachexia. Cachexia is a clinical diagnosis associated with weight loss, decreased muscle mass (sarcopenia), decreased strength, fatigue, and an increased inflammatory state. Patients with cachexia have a poorer prognosis than patients who have maintained their weight. Also, patients who have lost weight prior to initiating definitive therapy have worse side effects from subsequent therapy.
This study involves no treatment or invasive procedures. The chart review will attempt to characterize lung and pancreatic cancer related cachexia in the setting of a palliative care clinic including both primary treatment and treatment at the time of recurrence. Interventions in cachectic patients for weight control including nutritional support and supplements, pain control, anti-inflammatory medications, and appetite stimulants will be tracked along with clinical markers including weight and laboratory values.
Study Design
Outcome Measures
Primary Outcome Measures
- Prognosis and practice patterns in the management of cachexia and its associated symptoms. [10 years]
This study involves no treatment or invasive procedures. The chart review will attempt to characterize lung and gastrointestinal cancer related cachexia including both primary treatment and treatment at the time of recurrence. Interventions in cachectic patients for weight control including nutritional support and supplements, pain control, anti-inflammatory medications, and appetite stimulants will be tracked along with clinical markers, including weight and laboratory values.
Eligibility Criteria
Criteria
Inclusion Criteria:
Medical charts representing patients with a diagnosis of lung or gastrointestinal cancer with a tissue diagnosis from 1/1/2005 and onward treated at UT Southwestern or Parkland.
Exclusion Criteria:
There will be no absolute exclusion criteria as long as the inclusion criteria have been met.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- University of Texas Southwestern Medical Center
- Parkland Health and Hospital System
Investigators
- Principal Investigator: Puneeth Iyengar, MD, UT Southwestern Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- STU 092013-028